← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA168.6x16.4x20.6x
EV / LTM revenue210.7x1.6x3.6x
Premium to unaffected price2818%37%53%
Premium to 30-day VWAP1226%43%56%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
0482010: 3 deals, 0 clean on every measure201032011: 6 deals, 3 clean on every measure201162012: 6 deals, 3 clean on every measure201262013: 8 deals, 5 clean on every measure201382014: 2 deals, 2 clean on every measure201422015: 1 deals, 1 clean on every measure201512018: 5 deals, 3 clean on every measure201852020: 7 deals, 5 clean on every measure202072021: 2 deals, 2 clean on every measure202122022: 3 deals, 2 clean on every measure202232023: 8 deals, 5 clean on every measure202382024: 1 deals, 1 clean on every measure202412025: 2 deals, 1 clean on every measure202522026: 3 deals, 2 clean on every measure20263
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 17.8x median across 11 dealsHealthcare17.8xn=11Materials: 9.5x median across 5 dealsMaterials9.5xn=5
Deals by sector
Healthcare: 44 dealsHealthcare44Materials: 13 dealsMaterials13
Deals by buyer type
Financial sponsor: 6 dealsFinancial sponsor6Strategic: 28 dealsStrategic28Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 22 dealsUnclassified22
Deals by enterprise value
Under $250m: 29 dealsUnder $250m29$250m to $1bn: 12 deals$250m to $1bn12$1bn to $5bn: 11 deals$1bn to $5bn11$5bn to $20bn: 3 deals$5bn to $20bn3Over $20bn: 0 dealsOver $20bn0Not computed: 2 dealsNot computed2
Deals by industry code
Business Services & Software: 120 dealsBusiness Services & Sof…120Chemicals, Pharmaceuticals & Allied Products: 57 dealsChemicals, Pharmaceutic…57Real Estate: 33 dealsReal Estate33Holding & Other Investment Offices: 31 dealsHolding & Other Investm…31Electronics & Electrical Equipment: 30 dealsElectronics & Electrica…30Communications: 30 dealsCommunications30Oil & Gas Extraction: 26 dealsOil & Gas Extraction26Insurance Carriers: 24 dealsInsurance Carriers24Electric, Gas & Sanitary Services: 22 dealsElectric, Gas & Sanitar…22Health Services: 20 dealsHealth Services20
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
COSCIENS Biopharma Inc.
2026-04-20 (filed) · Take-private · $1.60 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value
Not named in the filing
Unclassified
Materials$5mn.a.n.a.
n.a.
SC 13E3
All cash
Aptose Biosciences Inc.
2026-01-15 (filed) · Take-private · $2.41 a share
Hanmi Pharmaceutical Co. LTD.
Strategic
Healthcare$5mn.a.n.a.
n.a.
28% to VWAP
SC 13E3
All cash
Cyanotech Corp
2026-01-09 (filed) · Take-private · $0.47 a share
Not named in the filing
Unclassified
Materials$11m28.0x0.4x
n.a.
SC 13E3
All cash
LakeShore Biopharma Co., Ltd.
2025-11-04 · Take-private · $0.90 a share
Board book on file →
Crystal Peak Holdings Inc.
Financial sponsor
Healthcare$61mn.a.0.7x
15%
SC 13E3
All cash
Anebulo Pharmaceuticals, Inc.
2025-07-23 (filed) · Take-private · $3.50 a share
Held out of the multiples: equity value 144 vs fee-table value 1
Not named in the filing
Unclassified
Healthcare$132mn.a.n.a.
n.a.
SC 13E3
All cash
Taro Pharmaceutical Industries Ltd
2024-02-15 (filed) · Take-private · $43.00 a share
Board book on file →
Libra Merger LTD.
Strategic
Healthcare$886m17.8x1.6x
48%
SC 13E3
All cash
Freeline Therapeutics Holdings plc
2023-12-08 (filed) · Take-private · $6.50 a share
Held out of the multiples: equity value 423 vs fee-table value 28
Board book on file →
Syncona Holdings LTD
Strategic
Healthcare$394mn.a.n.a.
51%
SC 13E3
All cash
Green Plains Partners LP
2023-09-16 · Take-private · $2.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; equity value 46 vs fee-table value 164
Board book on file →
GPLP Holdings Inc.
Strategic
Materials$88m1.8x1.1x
20%
21% to VWAP
SC 13E3
Includes stock
Liminal BioSciences Inc.
2023-08-17 (filed) · Take-private · $8.50 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value; equity value 264 vs fee-table value 11
Board book on file →
Thomvest Asset Management LTD.
Financial sponsor
Healthcare$264mn.a.n.a.
44%
SC 13E3
All cash
Gelesis Holdings, Inc.
2023-06-12 · Take-private · $0.06 a share
Board book on file →
Puretech Health PLC
Strategic
Healthcaren.a.n.a.n.a.
n.a.
SC 13E3
All cash
Paratek Pharmaceuticals, Inc.
2023-06-06 · Take-private · $2.15 a share
Board book on file →
Novo Holdings A/s
Strategic
Healthcare$336mn.a.2.0x
9%
20% to VWAP
SC 13E3
All cash
GreenLight Biosciences Holdings, PBC
2023-05-29 · Take-private · $0.30 a share
Alfa Holdings, Inc.
Financial sponsor
Healthcare$13mn.a.1.3x
n.a.
SC 13E3
All cash
Satsuma Pharmaceuticals, Inc.
2023-04-16 · Take-private · $0.91 a share
Shin Nippon Biomedical Laboratories, Ltd.
Strategic
Healthcare-$11mn.a.n.a.
n.a.
SC 13E3
All cash
Diversey Holdings, Ltd.
2023-03-08 · Take-private · $8.40 a share
Board book on file →
Bain Capital Fund XI, LP
Financial sponsor
Materials$4.5bn65.7x1.6x
41%
SC 13E3
All cash
AgroFresh Solutions, Inc.
2022-11-21 · Take-private · $3.00 a share
Held out of the multiples: EV / LTM EBITDA 77.5x outside 1x to 75x
Board book on file →
Not named in the filing
Financial sponsor
Materials$380m77.5x2.2x
79%
SC 13E3
All cash
Myovant Sciences Ltd.
2022-10-23 · Take-private · $27.00 a share
Board book on file →
Sumitomo Pharma Co., LTD.
Strategic
Healthcare$2.2bnn.a.6.7x
50%
48% to VWAP
SC 13E3
All cash
Stealth BioTherapeutics Corp
2022-07-31 · Take-private · $0.38 a share
Board book on file →
Equal Talent Investments LTD
Financial sponsor
Healthcare$234mn.a.n.a.
34%
SC 13E3
All cash
W R Grace & Co
2021-04-26 · Take-private · $70.00 a share
Board book on file →
Not named in the filing
Strategic
Materials$6.3bnn.a.3.6x
59%
54% to VWAP
SC 13E3
All cash
Heron Lake BioEnergy, LLC
2021-03-24 · Take-private · $0.36 a share
Board book on file →
Granite Falls Energy, LLC
Strategic
Materialsn.a.n.a.n.a.
n.a.
SC 13E3
All cash
China Biologic Products Holdings, Inc.
2020-11-19 · Take-private · $120.00 a share
Centurium Capital Partners 2018, L.P.
Strategic
Healthcare$4.5bn23.4x8.8x
n.a.
SC 13E3
All cash
Urovant Sciences Ltd.
2020-11-12 · Take-private · $16.25 a share
Board book on file →
Sumitomo Dainippon Pharma Co., LTD.
Strategic
Healthcare$611mn.a.n.a.
96%
92% to VWAP
SC 13E3
All cash
Reliv International Inc
2020-10-22 (filed) · Take-private · $3.75 a share
Not named in the filing
Controlling holder
Healthcare$5m15.0x0.1x
n.a.
SC 13E3
All cash
Akcea Therapeutics, Inc.
2020-08-30 · Take-private · $18.15 a share
Board book on file →
Ionis Pharmaceuticals Inc
Strategic
Healthcare$1.5bnn.a.4.3x
42%
55% to VWAP
SC 13E3
All cash
Cellular Biomedicine Group, Inc.
2020-08-11 · Take-private · $19.75 a share
Held out of the multiples: EV / LTM revenue 1299.0x above 60x
Board book on file →
CBMG Holdings
Strategic
Healthcare$390mn.a.1299.0x
12%
SC 13E3
All cash
Bioceres Crop Solutions Corp.
2020-07-27 (filed) · Take-private · $0.45 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value
Not named in the filing
Strategic
Materials$16mn.a.n.a.
n.a.
SC 13E3
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More